The remaining cancers (‘average’) locate between these two extremes, with mutant genes of maximum sample coverage ranging from 14.3% (TP53 in prostate cancers) to 47.6% (TTN in urinary tract cancers). This evidence concerns the gene TP53 and prostate carcinoma.